SCHEMBL4920567

SCHEMBL4920567

CCc1cccc(NC(=O)NCCc2cccs2)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 9/20 0.64
MEN1 O00255 8/20 0.64
MAPT P10636 7/20 0.64
RAB9A P51151 6/20 0.64
NPC1 O15118 5/20 0.64
SMN1; SMN2 Q16637 4/20 0.64
GAA P10253 1/20 0.64
ALOX15 P16050 1/20 0.64
CA12 O43570 1/20 0.53
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
CA9 Q16790 1/20 0.53
MAPK1 P28482 1/20 0.48
MMP12 P39900 2/20 0.47
MMP13 P45452 2/20 0.47
TP53 P04637 1/20 0.47
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4922773 0.86 CA12 (0.62) KMT2AMEN1MAPTRAB9ANPC1
SCHEMBL4926246 0.82 MEN1 (0.64) KMT2AMEN1MAPTRAB9ANPC1
SCHEMBL4917108 0.82 CA12 (0.65) KMT2AMEN1RAB9ANPC1SMN1; SMN2
SCHEMBL7463664 0.80 MAPT (0.70) KMT2AMEN1MAPTRAB9ANPC1
SCHEMBL4921458 0.78 NPC1 (0.67) KMT2AMEN1MAPTRAB9ANPC1
SCHEMBL4916720 0.78 MAPT (0.62) KMT2AMEN1MAPTRAB9ANPC1
SCHEMBL6380798 0.78 MAPT (0.56) KMT2AMEN1MAPTRAB9ANPC1
SCHEMBL14465082 0.78 CA12 (0.58) KMT2AMEN1RAB9ANPC1SMN1; SMN2
SCHEMBL24211435 0.77 MAPT (0.61) KMT2AMEN1MAPTRAB9ANPC1
SCHEMBL15601832 0.77 MAPT (0.55) KMT2AMEN1MAPTRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US claimed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US claimed
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US disclosed
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R KMT2A 1905/4885MEN1 4843/4885MAPT 4151/4885
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R KMT2A 1905/4885MEN1 4843/4885MAPT 4151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.